www.fdanews.com/articles/122997-jazz-pharmaceuticals-submits-nda-for-jzp-6-for-fibromyalgia
Jazz Pharmaceuticals Submits NDA for JZP-6 for Fibromyalgia
December 15, 2009
Jazz Pharmaceuticals, Inc. announced it has submitted a New Drug Application
(NDA) to the U.S. Food and Drug Administration for JZP-6 (sodium oxybate oral solution) for the treatment of fibromyalgia.
Fox Business
Fox Business